Congruence gets $32 million financing to advance genetic obesity candidate drug

CGX-926 is the first clinical candidate addressing MC4R-deficient genetic obesity

Biocytogen and Merck to advance antibody-conjugated lipid-based delivery solutions

Biocytogen will provide proprietary, fully human antibodies derived from its RenMice platform for evaluation in Merck’s antibody-conjugated LNP services

FDA grants Fast Track Designation for Teva’s Emrusolmin

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development

Argo Biopharma inks $5.2 billion deal with Novartis for novel molecules for cardiovascular diseases

Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity

HealthEdge and UST HealthProof Merge to create AI-powered healthcare payer technology

Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans

Strides partners with Kenox to expand nasal spray portfolio for US market

Kenox to provide formulation and development expertise in orally inhaled and nasal drug products

Aptar Pharma partners with Dianosic to advance ARIS platform for treatment of chronic allergic rhinitis and rhinosinusitis

Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods

Poly Medicure to acquire 90% stake in PendraCare Group for € 18.3 million

PendraCare Group develops, manufactures and sells innovative cardiology catheter solutions and provides design, development and manufacturing services to other global OEM’s

Jagsonpal Pharmaceuticals appoints Amrut Medhekar as Chief Operating Officer

CapVest to acquire majority stake in STADA

Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth